NEW YORK (GenomeWeb News) – The Dana-Farber Cancer Institute will use InforSense’s ClinicalSense cohort selection and clinical decision support product in its oncology research and patient care, the partners announced today.
Under a three-year agreement, researchers at Cambridge, Mass.-based Dana-Farber are using the web-based platform to access integrated clinical, sample, and research data via non-technical web pages. ClinicalSense enables researchers to slice and dice summary clinical data, compare sample relevant characteristics, and select sample subsets for optimal study design, according to the partners. The data is then analyzed by the InforSense platform to identify biomarkers or develop predictive models.
"At the Dana-Farber Cancer Institute, we need to have access to a wide range of clinical, experimental and patient specimen data that exists in disparate data stores,” said John Quackenbush, professor of biostatistics and computational biology at Dana-Farber, in a statement. “To drive cancer research and advance cancer care, we need an efficient way to integrate this data and make it available to a diverse group of developers, statisticians, study designers, and biologists.”
He said the InforSense platforms would enable analyses that can be rapidly developed, modified, and deployed among the institute’s researchers via a web interface.